What is the regional analysis of Atorvastatin API Market?
Atorvastatin API Market Highlights
The atorvastatin
API market size is anticipated to reach USD 2,852.3 Million
by 2030 at 7.50% CAGR during the forecast period 2022-2030.
North
America accounted for the largest market share of 40.64% in 2017, and the
regional market is projected to register a CAGR of 3.10% during the forecast
period. Asia-Pacific is expected to register the fastest CAGR. The Chinese
market is projected to exhibit the highest growth rate of 5.86% during the
forecast period from 2022 to 2030.
Atorvastatin API Market Segmentation
The atorvastatin API market outlook has been studied extensively by MRFR experts,
with respect to applications.
The key applications covered in the market
report are hypertriglyceridemia, dyslipidemia, hypercholesterolemia, and more.
Out of these, the hypercholesterolemia category can take the lead in the global
market and touch a valuation of USD 210,753.23 thousand by 2023-end, estimates
MRFR. Hypercholesterolemia cases across the globe have doubled in recent years,
given the increasing adoption of lifestyle choices like bad eating habits,
tobacco consumption and lack of exercise, all of which increase the cholesterol
level in the blood. Some other secondary factors giving rise to these cases can
be dialysis, alcohol intake, diabetes mellitus (Type 2), monoclonal gammopathy,
obesity, and more. In a nutshell, the growing prevalence of
hypercholesterolemia worldwide can help the segment record the fastest CAGR of
4.09% between 2018 and 2023.
Atorvastatin API Market Regional Analysis
Some of the key markets for atorvastatin API
globally include Europe, Asia Pacific/APAC coupled with Europe and North
America.
In 2017, with the biggest share of 40.64%,
North America secured the lead in the global market and is projected to record
a CAGR of 3.10% during the conjectured period. An alarming surge in heart
diseases in conjunction with bad eating habits and rise in obesity are major
reasons behind the market lucrativeness in the region. Technological
innovations in drugs along with the expanding supply channel networks of
leading firms in the region also adds to the projected growth.
APAC is a promising market and is soon
expected to garner the fastest growth rate, while China can be the fastest
expanding market in the region, with a rate of 5.86% from 2018 to 2023. Growing employment rate, surge in hectic
lifestyles and mounting health concerns among people have led to higher demand
for atorvastatin APIs in the pharma industry. Promising pipelines and the spike
in hypercholesterolemia cases also bolster the market growth in the region.
The European industry is presumed to cross USD
131,094.04 thousand by the year 2023, thanks to the massive prevalence of
hypercholesterolemia as well as mixed dyslipidemia. France, followed by the UK,
is the biggest gainer in the regional market, as most of the pharmaceutical
companies in the country are striving to expedite their research and
development to produce huge volumes of drugs.
Atorvastatin API Market Players
The global atorvastatin API market players are
Teva Pharmaceutical Industries Ltd (Israel), Jubilant Life Sciences Ltd
(India), Dr. Reddy’s Laboratories Ltd (India), Sun Pharmaceutical Industries
Ltd (India), Ind-Swift Labs Ltd (India), Morepen Laboratories Ltd (India),
Zhejiang Hisun Pharmaceutical Co Ltd (China), Anuh Pharma Ltd (India),
Centrient Pharmaceuticals (The Netherlands) and Cadila Pharmaceuticals (India)
About
Market Research Future:
At Market Research Future
(MRFR), we enable our customers to unravel the complexity of various industries
through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR),
& Consulting Services. MRFR team have supreme objective to provide the
optimum quality market research and intelligence services to our clients.
Contact us:
Market Research
Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street,
5Th Floor,
New York, New York
10013
United States of
America
+1 628 258 0071
Email: sales@marketresearchfuture.com
Comments
Post a Comment